A Study of Levornidazole Disodium Phosphate for Injection vs. Ornidazole in Treatment of Postoperative Intra-Abdominal Infections Caused by Anaerobic Bacteria

Exclusion criteria

• . Those with known or suspected allergies to nitroimidazoles
• . Patients who have participated in other studies and used investigational drugs of other studies within 3 months prior to screening
• . Patients who are taking other medications or have other diseases that may interfere with the evaluation of the safety or effectiveness of the drug; Or patients who are at risk of serious drug interactions due to concomitant medications(such as warfarin, as well as medications with compatibility contraindications to levornidazole, including furbencillin sodium, nafcillin sodium, omeprazole, vorbizole, potassium sodium dehydroandrographolide succinate for injection, azlocillin sodium, etc.)
• . patients who have poor compliance and cannot complete the expected course of treatment and follow-up in the opinion of the investigator
• . Abnormal liver function (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 1.5 times the upper limit of the normal value; for patients with acute biliary tract infection or combined liver abscess, it can be relaxed to \> 3 times the upper limit of the normal value); or abnormal kidney function (creatinine clearance rate ≤ 60 mL/min/1.73 m² \[Cockcroft - Gault formula\])
• . Patients with serious primary diseases of important organs and systems such as cardiovascular, nervous system, endocrine system, hematopoietic system (such as heart failure, leukemia, uncontrolled diabetes, etc.), or those with malignant tumors
• . Women during pregnancy or lactation, or women of childbearing age with a positive pregnancy test result before the trial
• . Women of childbearing age and men who cannot take effective contraceptive measures during the trial period. The time limit is from the signing of the informed consent form to 3 months after the last dose